Disruption expected as six-day doctors' strike begins Cancer patient furious as strike delays appointment Don't put off treatment during doctors' strike, NHS … 'Two weeks will make such a difference': UK first as… AR tech prepares patients for endometriosis surgery Men's group hopes to ease strain on NHS services Prince William praises £20m milestone for Bowelbabe … Review finds 250 patients need repeat bone scans Digital technologies for applying algorithms to spir… Fewer heat-related deaths in 2025 despite warmest su… Disruption expected as six-day doctors' strike begins Cancer patient furious as strike delays appointment Don't put off treatment during doctors' strike, NHS … 'Two weeks will make such a difference': UK first as… AR tech prepares patients for endometriosis surgery Men's group hopes to ease strain on NHS services Prince William praises £20m milestone for Bowelbabe … Review finds 250 patients need repeat bone scans Digital technologies for applying algorithms to spir… Fewer heat-related deaths in 2025 despite warmest su…

Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Men's Health Dermatology Rare Diseases

Home › Oncology › Clinical Trial

Clinical Trial Enrolling PHASE1, PHASE2

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas. Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Interventions: S095029, pembrolizumab 200 mg (KEYTRUDA ®) Lead Sponsor: Servier Bio-Innovation LLC Planned Enrollment: 48 […]

📅 03 Apr 2026 ⏱ 1 min read

Enrolling

Check the registry for current status and eligibility criteria.

Status

Enrolling

Phase

PHASE1, PHASE2

Start

2024-08-31

Completion

2027-08

Key Clinical Points

• Early-stage trial testing a new antibody combined with pembrolizumab for advanced stomach cancer with specific genetic features.

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.

Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer

Interventions: S095029, pembrolizumab 200 mg (KEYTRUDA ®)

Lead Sponsor: Servier Bio-Innovation LLC

Planned Enrollment: 48 participants

Full Trial Details

View this trial on the source registry

Eligibility criteria, protocol, and results when available

Share: Twitter/X LinkedIn

🔬

Related

More Trials in Oncology

active not recruiting

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies